Asset profile
UCB0022
Small molecule
Evidence outlook · lead readout
NCT06055985 · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06055985: The study randomly assigned 207 participants to two UCB0022 dose groups or placebo, with participants, care providers, investigators, and outcome assessors masked. Its primary clinical endpoint was change in average daily OFF time, but no results are available to show whether the endpoint was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.